COMMUNIQUÉS West-GlobeNewswire

Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

07/11/2024 - 14:00

Preliminary results from Phase 1 ACESOT-1051 trial of WEE1 inhibitor, APR-1051, demonstrate the product to be well-tolerated with no unexpected toxicities Philippe Pultar, MD engaged as senior medical advisor to support [...]

Orchestra BioMed to Participate in Jefferies London Healthcare Conference

07/11/2024 - 14:00

NEW HOPE, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk- [...]

Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024

07/11/2024 - 14:00

NEEDHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL ), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]

MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update

07/11/2024 - 14:00

Total gross proceeds from upsized initial public offering and Series C financing were approximately $251.2 million Last subject last visit in Phase 1 trial of MBX 1416 anticipated by late November; topline results to be [...]

Inotiv, Inc. to Participate in Upcoming Jefferies and Craig-Hallum Investor Conferences

07/11/2024 - 14:00

WEST LAFAYETTE, Ind., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and [...]

HilleVax Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress

07/11/2024 - 14:00

$189.3 million of cash, cash equivalents and marketable securities as of September 30, 2024 The company is exploring the potential for continued development of its norovirus vaccine candidates in adults as well as [...]

PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results

07/11/2024 - 14:00

Enrollment on track in Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more than 75% of sites activated across the U. [...]

Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13

07/11/2024 - 14:00

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the [...]

CRISPR Therapeutics to Present at the Guggenheim Inaugural Healthcare Innovation Conference

07/11/2024 - 14:00

ZUG, Switzerland and BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today [...]

Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

07/11/2024 - 14:00

Presented positive 96-week long-term eGFR stabilization data from ORIGIN Ph 2b clinical trial of atacicept in IgAN in a late-breaking oral presentation at the American Society of Nephrology (ASN) Kidney Week 2024 with [...]

Bionomics to Present at the 2024 CNS Summit

07/11/2024 - 14:00

ADELAIDE, Australia and CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric [...]

Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million

07/11/2024 - 14:00

Celularity Raises Full Year 2024 Expected Net Sales Guidance to $54 Million to $60 Million, Compared to Previous Guidance of $50 Million to $56 Million October Expected Net Sales of $8.3 Million to $8.9 Million Marks [...]

VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

07/11/2024 - 14:00

VYN201 Phase 2b vitiligo trial exceeds enrollment target; Expected to be fully enrolled in December 2024 with top-line results on track for mid-2025 Reported positive first-in-human Phase 1a SAD data for VYN202, with [...]

Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist

07/11/2024 - 14:00

MALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- via IBN -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for [...]

Better Choice Company to Present at the Sidoti Micro Cap 2024 Virtual Conference

07/11/2024 - 14:00

TAMPA, Fla., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Better Choice Company (NYSE: BTTR) (“Better Choice” or “the Company”), a pet health and wellness company, today announced that management will be participating at the [...]

Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024

07/11/2024 - 14:00

SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, will host a conference call and live webcast at 4:30 p.m. Eastern Time on [...]

Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024

07/11/2024 - 14:00

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in Citi’s 2024 Global Healthcare [...]

Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024

07/11/2024 - 14:00

REYKJAVIK, Iceland, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its [...]

DiagnaMed Files U.S. Patent Application for Novel Methods of Producing Molecular Hydrogen

07/11/2024 - 14:00

Advancing molecular hydrogen for neurological and mental health disorders Expects its molecular hydrogen product to be ready for use in December 2024 TORONTO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp [...]